Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
32 Results for "
Autophagy-lysosome
" in MedChemExpress (MCE) Product Catalog:
Products (32)
32 Results for "Autophagy-lysosome" in MCE Product Catalog:
1
1 Cited Publications
NEO214 is an autophagy inhibitor and a covalent conjugate of the PDE4 inhibitor Rolipram (HY-16900) and perillyl alcohol (HY-N7000). It has anti-cancer activity and blood-brain barrier (BBB) permeability. Over sex. NEO214 prevents autophagy-lysosome fusion, thereby blocking autophagic flux and triggering glioma cell death. The process involves mTOR activation, andTFEB(Transcription Factor EB) aggregation. NEO214 inhibitionMacroautophagy/autophagy in glioblastoma cells has the potential to overcome chemotherapy resistance in glioblastoma .
Research Areas:
PROTAC α-synuclein degrader 5 is a selective PROTAC degrader targeting α‑synuclein aggregates, with a DC50 of 7.51 μM. PROTAC α-synuclein degrader 5 binds to αSyn aggregates, recruits the CRBN E3 ubiquitin ligase, and mediates the ubiquitination and subsequent degradation of α‑synuclein aggregates. PROTAC α-synuclein degrader 5 activates the autophagy-lysosome pathway. PROTAC α-synuclein degrader 5 reduces ROS levels in neuroblastoma cells, restores mitochondrial membrane potential, rescues cell viability, and decreases LDH release. PROTAC α-synuclein degrader 5 degrades αSyn aggregates in Caenorhabditis elegans and ameliorates oxidative stress. PROTAC α-synuclein degrader 5 is used for the research of synucleinopathies, such as Parkinson's disease .
Cat. No.: HY-175839
Target:
Research Areas:
PROTAC EGFR degrader 15 is a Pomalidomide (HY-10984)-based Gefitinib (HY-50895) EGFR PROTAC degrader. PROTAC EGFR degrader 15 triggers EGFR degradation via ubiquitin-proteasome-dependent proteolysis and autophagy-lysosome activation pathways. PROTAC EGFR degrader 15 targets ETFA to enhance ATP production. PROTAC EGFR degrader 15 significantly suppresses tumor growth in a Gefitinib-acquired resistant HCC-827 xenograft model. PROTAC EGFR degrader 15 can be used for the study of non-small cell lung cancer (NSCLC) .
Research Areas:
PROTAC GPX4 degrader-1 is a glutathione peroxidase 4 (GPX4) PROTAC degrader with a DC50 of 30 nM. PROTAC GPX4 degrader-1 induces ROS accumulation and ferroptosis in cancer cells. PROTAC GPX4 degrader-1 inhibits cell growth and reduces GPX4 levels in tumor tissues. PROTAC GPX4 degrader-1 can be used in research related to various cancers including fibrosarcoma, non-small cell lung cancer, and melanoma .
Cat. No.: HY-N2991
CAS No.: 77012-31-8
Category:
Target:
Research Areas:
MS9427 is a potent PROTAC EGFR degrader with Kds of 7.1 nM and 4.3 nM for EGFR WT and EGFR L858R, respectively. MS9427 selectively degrades the mutant but not the WT EGFR through both the ubiquitin/proteasome system (UPS) and autophagy/lysosome pathways. MS9427 potently inhibits the proliferation of NSCLC cells. MS9427 can be used for researching anticancer .
MS9449 is a potent PROTAC EGFR degrader, with Kd values of 17 nM and 10 nM for wild-type EGFR and mutant EGFR L858R, respectively, and a DC50 of 7.1 nM for EGFR Del19. MS9449 effectively induces the degradation of mutant EGFR through the ubiquitin-proteasome system (UPS) and the autophagy-lysosome pathway. MS9449 exhibits anticancer activity against non-small cell lung cancer. MS9449 can be applied in related research on non-small cell lung cancer .
Cat. No.: HY-176130
CAS No.: 3115333-82-6
Target:
Research Areas:
MRL828 is a heterobifunctional molecule that targets aggregated tau protein. As an autophagy-targeting chimera (ATTEC), MRL828 selectively labels aggregated tau protein for clearance via the autophagy (autophagy)-lysosome pathway. The activity of MRL828 depends on autophagosomes rather than lysosomes, and it induces autophagosome-dependent secretion. MRL828 acts as an intracellular aggregate inhibitor and a secretory autophagy inducer, reducing intracellular levels of aggregated tau protein through autophagosome-dependent secretory autophagy instead of lysosomal degradation. MRL828 can be used in the research of neurodegenerative diseases such as Alzheimer's disease .
Cat. No.: HY-147941A
Purity: 99.01%
Research Areas:
MS9427 TFA is a potent PROTAC EGFR degrader with Kds of 7.1 nM and 4.3 nM for EGFR WT and EGFR L858R, respectively. MS9427 TFA selectively degrades the mutant but not the WT EGFR through both the ubiquitin/proteasome system (UPS) and autophagy/lysosome pathways. MS9427 TFA potently inhibits the proliferation of NSCLC cells. MS9427 TFA can be used for researching anticancer .
Cat. No.: HY-157788
Research Areas:
ZX703 is a GPX4 PROTAC degrader with a DC50 of 0.135 μM. ZX703 degrades GPX4 via the ubiquitin-proteasome and autophagy-lysosome pathways. ZX703 induces the accumulation of ROS, thereby triggering Ferroptosis. ZX703 can be used in studies related to fibrosarcoma and prostate cancer .
Cat. No.: HY-176451
CDK9 degrader-1 is a HyT-type CDK9 degrader that selectively induces protein degradation by recruiting ATG101 (with a DC50 of 0.4073 μM in HCT116 cells). CDK9 degrader-1 recruits ATG101 to initiate the autophagy-lysosome pathway, forming LC3-containing autophagosomes that fuse with lysosomes to degrade CDK9. CDK9 degrader-1 mediates the degradation of Cyclin T1 via the same autophagy-lysosome pathway. CDK9 degrader-1 induces downstream phenotypic effects associated with CDK9 degradation. CDK9 degrader-1 can be used in the research of colorectal cancer (Blue: hydrophobic group; Pnk: CDK9 ligand (HY-50940); Black: linker (HY-N0420)) .
Cat. No.: HY-169363
Target:
Research Areas:
PD-L1 degrader-2 (Compound B3) is an orally active AUTAC degrader, that degrades PD-L1 through autophagy-lysosome pathway with a DC50 of 0.5 μM. PD-L1 degrader-2 exhibits inhibitory activity against PD-1/PD-L1 interaction with an IC50 of 22.8 nM. PD-L1 degrader-2 upregulates the expressions of Atg9b, Lamp1 and Mitf, and activates the autophagy lysosome system. PD-L1 degrader- exhibits antitumor efficacy in CT26 mouse model . (Pink: autophagy-lysosome activator (HY-159894); Black: linker (HY-W015088); Blue: PD-L1 ligand (HY-169365))
Cat. No.: HY-168892
CAS No.: 380636-64-6
LC3B recruiter 2 (34R) is an LC3B recruiter and a component of the autophagy-lysosome pathway degradation system (ATTEC, Autophagy-Tethering Compounds), which directly binds to LC3B. LC3B recruiter 2 binds to CDK9 inhibitor SNS-032 (HY-10008) through a linker, forming an ATTEC that targets the degradation of the CDK9 and Cyclin T1 complex (with inhibitory effects on both). Therefore, LC3B recruiter 2 exerts activity through the LC3B-dependent autophagy-lysosome pathway, interfering with the cell cycle of cancer cells, thus exhibiting antitumor activity .
Cat. No.: HY-156795
CAS No.: 3020773-91-2
Target:
Research Areas:
CDK9/CycT1 degrader-1 is an autophagy-anchored bifunctional degrader that mediates the degradation of the CDK9/cyclin T1 protein complex. CDK9/CycT1 degrader-1 binds both CDK9 and LC3B simultaneously to form a ternary complex, achieving target protein degradation via the autophagy-lysosome pathway. CDK9/CycT1 degrader-1 downregulates the protein levels of Mcl‑1 and c‑Myc and induces apoptosis. PROTAC CDK9/CycT1 Degrader-2 is applicable to cancer-related research .
Cat. No.: HY-169365
CAS No.: 2766689-18-1
Target:
Research Areas:
2-Methylbiphenyl-oxadiazole-NH-Ph-CHO is a PD-L1 ligand. 2-Methylbiphenyl-oxadiazole-NH-Ph-CHO serves as the PD-L1 ligand of AUTAC PDL1 degrader-2 (HY-169363). 2-Methylbiphenyl-oxadiazole-NH-Ph-CHO activates the autophagy-lysosome system and upregulates autophagy-lysosome-related genes. 2-Methylbiphenyl-oxadiazole-NH-Ph-CHO is applicable for cancer research .
Cat. No.: HY-N2991R
CAS No.: 77012-31-8
Category:
Target:
Cat. No.: HY-156083
CAS No.: 3020773-81-0
Target:
Research Areas:
CDK9 degrader-2 is a bifunctional degrader of ATTEC (Autophagy-Tethering Compound) that degrades the CDK9/cyclin T1 complex. CDK9 degrader-2 forms a ternary complex with CDK9 and LC3B, and achieves degradation through the autophagy-lysosome pathway, a process independent of the ubiquitin-proteasome system. CDK9 degrader-2 downregulates the expression of Mcl-1 and c-Myc proteins, induces apoptosis, and exhibits antitumor activity in in vivo MV4-11 xenograft models. CDK9 degrader-2 can be used for leukemia research .
Cat. No.: HY-170989
Target:
Research Areas:
BRD4 degrader-5 (Compound 23) is a hydrophobic tag (HyTag)-based protein degrader for BRD4 (DC50 = 24.7 μM) through ER stress and autophagy-lysosome pathway. BRD4 degrader-5 inhibits the proliferation of cancer cell 4T1 with an IC50 of 20.6 μM .
Cat. No.: HY-169364
Target:
Research Areas:
2-Methylbiphenyl-oxadiazole-NH-Ph-NH-PEG3-C2-NH-Boc serves as the PD-L1 ligand-linker conjugate of AUTAC PDL1 degrader-2 (HY-169363). 2-Methylbiphenyl-oxadiazole-NH-Ph-NH-PEG3-C2-NH-Boc is applicable to AUTAC synthesis. It is also used in the research of colorectal cancer .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
